INFANRIX HEXA – (1,890) Vaccine Service at Dr. Essa Lab

INFANRIX HEXA – (1,890) at Dr. Essa Lab

INFANRIX HEXA – (1,890) is a highly advanced, combined pediatric vaccine designed to protect infants and young children against six major infectious diseases in a single immunization series. Administered at Dr. Essa Lab, this 6-in-1 vaccine represents a cornerstone of modern preventive pediatrics, offering comprehensive protection while significantly reducing the number of injections a child must receive. The vaccine targets diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib), such as meningitis and pneumonia. By integrating these six critical antigens into a single formulation, INFANRIX HEXA – (1,890) simplifies the pediatric immunization schedule, enhances compliance, and minimizes physical and emotional distress for both infants and their parents.

At Dr. Essa Lab, we prioritize the health and safety of your child by ensuring that all immunizations are administered under the strictest clinical protocols. The INFANRIX HEXA – (1,890) vaccine works by introducing small, safe, and inactive components of the target pathogens into the infant's body. These components, known as antigens, stimulate the child's immune system to produce specific protective proteins called antibodies. If the child is exposed to any of these six pathogens in the future, their immune system will immediately recognize the threat and neutralize it, preventing serious illness. Dr. Essa Lab maintains a state-of-the-art cold chain management system to preserve the potency and efficacy of this delicate vaccine from storage to administration, ensuring maximum diagnostic and preventive value for families across Karachi and Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

Preparing your infant for the INFANRIX HEXA – (1,890) vaccination at Dr. Essa Lab involves a few simple steps to ensure a safe and comfortable experience. Please adhere to the following preparation guidelines:

• Health Assessment: Ensure your infant is in good general health. If your child has a high fever or an acute moderate-to-severe illness, consult your pediatrician, as the vaccination may need to be temporarily postponed. Mild illnesses, such as a common cold or mild cough, are generally not contraindications.
• Vaccination Record: Always bring your child's official immunization card or vaccination record booklet to Dr. Essa Lab. Accurate documentation is essential for tracking vaccine doses and intervals.
• Feeding and Comfort: It is highly recommended to feed your baby about 30 minutes before the appointment to prevent hunger-induced irritability. Dress your infant in loose, comfortable clothing that allows easy access to the thigh area.
• Medical History Disclosure: Inform the healthcare professional at Dr. Essa Lab if your child has any known allergies (especially to neomycin, polymyxin, or previous vaccines), a history of bleeding disorders, or has experienced any adverse reactions after prior immunizations.

During the Procedure

The administration of INFANRIX HEXA – (1,890) at Dr. Essa Lab is conducted by highly trained pediatric nurses and medical professionals who specialize in gentle, child-friendly care. The procedure follows these precise steps:

• Positioning: You will be asked to hold your infant securely in your lap in a comfortable, calming position. This helps keep the child still and provides emotional reassurance during the injection.
• Injection Site Preparation: The vaccine is administered intramuscularly, typically into the anterolateral aspect of the infant's thigh (the vastus lateralis muscle), which is the safest and most effective site for infants. The nurse will thoroughly cleanse the skin with an antiseptic swab.
• Administration: Using a sterile, single-use syringe, the healthcare provider will swiftly and gently inject the reconstituted INFANRIX HEXA – (1,890) vaccine. The entire injection process takes only a few seconds.
• Post-Injection Observation: After the injection, a small adhesive bandage may be applied to the site. You will be advised to remain in the waiting area at Dr. Essa Lab for approximately 15 to 30 minutes. This routine observation period ensures that any immediate allergic reactions, though extremely rare, can be promptly managed by our medical team.

When is a INFANRIX HEXA – (1,890) Performed?

Primary Infantile Immunization Schedules

The primary series of INFANRIX HEXA – (1,890) is typically initiated in early infancy, starting as early as six weeks of age. Pediatricians request this vaccine at specific intervals (usually at 2, 4, and 6 months, or according to local national immunization guidelines) to build early, robust immunity. Early administration is critical because infants are highly vulnerable to life-threatening infections like pertussis and Haemophilus influenzae type b during their first year of life.

Prevention of Diphtheria, Tetanus, and Pertussis

Physicians prescribe this vaccine to protect infants from the severe clinical consequences of diphtheria, tetanus, and pertussis. Diphtheria can cause a thick membrane to form in the throat, leading to severe breathing difficulties. Tetanus, or lockjaw, causes painful muscle spasms and can be fatal. Pertussis, or whooping cough, leads to violent coughing fits that make it hard for infants to breathe, eat, or drink. INFANRIX HEXA – (1,890) provides highly effective active immunization against all three conditions.

Protection Against Hepatitis B and Poliomyelitis

Hepatitis B is a serious viral infection that attacks the liver and can lead to lifelong chronic infection, liver failure, or liver cancer. Poliomyelitis is a highly infectious viral disease that can invade the nervous system and cause irreversible paralysis or death. This 6-in-1 vaccine is requested by clinicians to ensure that infants receive early, comprehensive protection against both of these devastating viral pathogens, eliminating the need for separate, multiple injections.

Prevention of Invasive Haemophilus Influenzae Type B (Hib)

Haemophilus influenzae type b is a bacterium responsible for severe, invasive pediatric infections, including bacterial meningitis (infection of the brain cover), epiglottitis (severe swelling of the throat that can block breathing), pneumonia, and bacteremia (blood poisoning). Because Hib infections can progress rapidly and become life-threatening within hours, physicians rely on the INFANRIX HEXA – (1,890) vaccine to stimulate protective antibodies early in life.

Booster Dosing and Catch-Up Immunization

In addition to the primary infantile series, INFANRIX HEXA – (1,890) may be administered as a booster dose in the second year of life to prolong immunity. It may also be recommended by pediatricians for catch-up vaccination schedules in children who have missed their scheduled doses. The vaccine ensures that the child's immunological memory is reinforced, providing long-term protection throughout early childhood.

What Does a INFANRIX HEXA – (1,890) Detect?

As an active immunizing agent, INFANRIX HEXA – (1,890) does not detect active diseases; rather, it stimulates, targets, and prepares the infant's immune system to recognize and neutralize specific pathogenic antigens. The vaccine targets and prevents the following clinical conditions, pathogens, and immunological parameters:

• Corynebacterium diphtheriae Toxoid: Stimulates the production of neutralizing antibodies against the diphtheria toxin.
• Clostridium tetani Toxoid: Induces active immunity against the neurotoxin responsible for tetanus.
• Bordetella pertussis Antigens: Contains pertussis toxoid, filamentous haemagglutinin, and pertactin to prevent whooping cough.
• Hepatitis B Surface Antigen (HBsAg): Promotes the development of protective anti-HBs antibodies to prevent liver infection.
• Poliovirus Type 1 (Inactivated): Stimulates systemic immunity against the Mahoney strain of poliovirus.
• Poliovirus Type 2 (Inactivated): Provides neuroprotection against the MEF-1 strain of poliovirus.
• Poliovirus Type 3 (Inactivated): Induces protective antibodies against the Saukett strain of poliovirus.
• Haemophilus influenzae Type B Polysaccharide: Conjugated to tetanus toxoid to stimulate robust antibody responses in young infants.
• Prevention of Pediatric Bacterial Meningitis: Protects against brain inflammation caused by Haemophilus influenzae type b.
• Prevention of Acute Epiglottitis: Minimizes the risk of life-threatening airway obstruction due to Hib infection.
• Prevention of Infantile Tetanus (Lockjaw): Eliminates the risk of painful, generalized muscle spasms.
• Prevention of Whooping Cough Paroxysms: Reduces the incidence of severe, exhausting coughing spells in infants.
• Prevention of Chronic Hepatitis B Carrier State: Protects against long-term liver damage and cirrhosis.
• Prevention of Hepatocellular Carcinoma: Lowers the long-term risk of liver cancer associated with chronic HBV.
• Prevention of Acute Flaccid Paralysis: Protects the central nervous system from poliovirus-induced damage.
• Prevention of Pseudomembranous Pharyngitis: Prevents the formation of obstructive throat membranes caused by diphtheria.
• Prevention of Hib-Induced Septic Arthritis: Protects infant joints from severe bacterial infection.
• Prevention of Infantile Bronchopneumonia: Reduces the risk of severe lung infections caused by Hib or pertussis.
• Stimulation of Active Humoral Immunity: Promotes B-cell proliferation and specific antibody secretion.
• Induction of Immunological Memory: Activates T-helper cells to ensure long-term vaccine efficacy.
• Reduction of Community Transmission: Contributes to herd immunity against vaccine-preventable diseases.
• Prevention of Systemic Bacteremia: Prevents pathogens from entering and multiplying in the infant's bloodstream.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand the importance of maintaining an accurate and easily accessible medical record for your child. Immediately following the administration of the INFANRIX HEXA – (1,890) vaccine, our clinical staff will update your child's physical vaccination card with the date of administration, vaccine batch number, manufacturer details, and the scheduled date for the next dose. This physical record is handed over to you immediately. Additionally, Dr. Essa Lab logs all immunization records into our secure digital database. Parents can access their child's vaccination history and digital reports online through our official website or mobile application, ensuring that your family's health records are always secure and available whenever required for school admissions or pediatric consultations.

INFANRIX HEXA – (1,890) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Diphtheria Toxoid Antibodies	Protective antibody titers (≥0.1 IU/ml) post-series	Inadequate antibody response; susceptibility to infection
Tetanus Toxoid Antibodies	Protective antibody titers (≥0.1 IU/ml) post-series	Sub-therapeutic antibody levels; risk of tetanus infection
Pertussis Antibody Response	Significant rise in anti-PT, anti-FHA, and anti-PRN antibodies	Failure to seroconvert; persistent vulnerability to whooping cough
Hepatitis B Surface Antibodies	Anti-HBs titers ≥10 mIU/ml indicating long-term immunity	Anti-HBs titers <10 mIU/ml; lack of protective immunity
Poliovirus Antibodies (Types 1, 2, 3)	High neutralizing antibody titers against all three poliovirus types	Incomplete protection; vulnerability to specific poliovirus strains
Hib PRP Antibodies	Anti-PRP titers ≥0.15 µg/ml (short-term) or ≥1.0 µg/ml (long-term)	Low antibody levels; increased risk of invasive Hib diseases
Injection Site Assessment	No reaction, or mild, transient redness, swelling, and localized tenderness	Severe localized swelling, persistent pain, or sterile abscess formation
Post-Vaccination Temperature	Normal body temperature or mild, self-limiting low-grade fever (<38.5°C)	High-grade fever (≥39.5°C) or febrile convulsions (extremely rare)
Pediatric Vaccination Schedule	Age-appropriate administration of all primary and booster doses	Delayed or missed doses, leading to temporary gaps in immunity

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for INFANRIX HEXA – (1,890)?

• Experienced Healthcare Professionals: Our clinical team consists of highly trained pediatric nurses and vaccinators who ensure a gentle, safe, and stress-free experience for your infant.
• Patient-Focused Care: We prioritize the comfort and well-being of your child, providing a welcoming and child-friendly environment at all our centers.
• Strict Cold Chain Integrity: Dr. Essa Lab maintains advanced, continuous temperature-monitoring systems to ensure that vaccines are stored and handled at optimal temperatures, preserving their full potency.
• Quality Diagnostic and Preventive Services: As a trusted name in healthcare since 1987, we adhere to international standards of safety, hygiene, and clinical excellence.
• Convenient Locations: With an extensive network of branches across Karachi and other cities, accessing premium pediatric immunization services is convenient for families.
• Digital Record Management: We offer secure, instant access to your child's vaccination history and reports online through our website and dedicated mobile app.
• Authentic Vaccines: We source all vaccines, including INFANRIX HEXA – (1,890), directly from verified, reputable global manufacturers.
• Comprehensive Pediatric Support: Our staff is always available to provide post-vaccination guidance, helping you manage mild side effects like low-grade fever or localized redness at home.